Lixte Biotechnology (NASDAQ:NMAD) Issues Earnings Results

Lixte Biotechnology (NASDAQ:NMAD – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.74) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.47 million during the quarter.

Lixte Biotechnology Price Performance

NMAD stock traded down $0.59 during mid-day trading on Tuesday, reaching $2.21. The company had a trading volume of 216,604 shares, compared to its average volume of 199,611. The company has a market capitalization of $35.58 million, a price-to-earnings ratio of -2.21 and a beta of 1.37. Lixte Biotechnology has a 52 week low of $2.15 and a 52 week high of $8.38. The stock has a 50 day simple moving average of $3.73 and a two-hundred day simple moving average of $4.65.

Institutional Investors Weigh In On Lixte Biotechnology

Several large investors have recently made changes to their positions in the stock. Legacy Wealth Managment LLC ID bought a new position in shares of Lixte Biotechnology in the second quarter valued at $4,457,000. BlackRock Inc. bought a new stake in Lixte Biotechnology during the second quarter worth $564,000. FNY Investment Advisers LLC bought a new stake in Lixte Biotechnology during the second quarter worth $330,000. Finally, Equitable Holdings Inc. acquired a new stake in Lixte Biotechnology in the second quarter valued at $74,000. Institutional investors and hedge funds own 5.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NMAD shares. Wall Street Zen lowered Lixte Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings raised Lixte Biotechnology from a “sell (e)” rating to a “sell (d)” rating in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on Lixte Biotechnology

Lixte Biotechnology Company Profile

(Get Free Report)

Lixte Biotechnology Holdings is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on compounds that target protein phosphatase 2A (PP2A), an enzyme involved in cellular processes that can influence cancer growth and treatment response. The company’s lead investigational candidate, LB-100, is a small-molecule PP2A inhibitor being studied for potential use alongside existing cancer treatments. Lixte has described its approach as aiming to make tumors more responsive to therapies such as chemotherapy and immunotherapy.

Read More

Earnings History for Lixte Biotechnology (NASDAQ:NMAD)

Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.